Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model
about
High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivoPan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigsChlamydial Pre-Infection Protects from Subsequent Herpes Simplex Virus-2 Challenge in a Murine Vaginal Super-Infection Model.Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, ΔgD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2.
P2860
Q34331569-358D42D0-5F55-47C1-ADF7-3211C83EC369Q34350019-792C0F47-8847-4B81-8092-2F2334568C33Q35058245-FEE738F0-CAC9-4CE6-8BCE-AB7B2A486765Q35061783-F412C3CC-75E7-4AF7-ACBA-8EF0A24D768BQ35249684-53BCD1FA-B5F2-43A7-AF00-1C5A1E178F0CQ35883842-A6ADF9A1-8359-4931-9411-D51A449D0511Q36553837-E282F4A3-09F2-446A-AE1D-8AB310F1A5EAQ36824210-D965B770-9B6F-48FA-88EB-B19C79ED3861Q37611796-5C9C1C47-5B76-42BA-91E0-04C23AD0DFDDQ38212516-47689CE0-5ED8-491E-AD1F-856E1634CA7AQ38241377-BEF5EAB4-F7BF-4D4D-A1D9-71B2F5B2236BQ40443062-B494586F-5CB6-47FB-878D-CFB2094CDD63Q45325692-EB411500-6697-44A7-AB5A-A6573F5B943BQ47319374-D1BCA414-7806-4963-978B-474C2A72556C
P2860
Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@ast
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@en
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@nl
type
label
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@ast
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@en
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@nl
prefLabel
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@ast
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@en
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@nl
P2093
P2860
P1433
P1476
Immunogenicity and efficacy of ...... e 2 in the mouse genital model
@en
P2093
Changhong Zhou
Harry Kleanthous
Hector Hernandez
Jeffrey Almond
John Catalan
John F Hamberger
Joshua M DiNapoli
Mark Parrington
Patricia Londoño-Hayes
Simge Baloglu
P2860
P304
P356
10.1371/JOURNAL.PONE.0046714
P407
P577
2012-10-11T00:00:00Z